Staar Surgical (STAA) EBITDA (2010 - 2026)

Staar Surgical (STAA) has reported EBITDA for 17 consecutive years, with $10.1 million the latest figure, recorded in Q3 2026.

• For the quarter ending Q3 2026, EBITDA rose 133.71% year-over-year to $10.1 million; the trailing twelve-month figure through Jul 2026 stood at $13.7 million (up 112.53% YoY), and the FY2026 full-year result was -$91.7 million, down 627.25% from the prior year.
• EBITDA climbed to $10.1 million in Q3 2026 per STAA's latest filing, from $8.0 million in the prior quarter.
• Across five years, EBITDA topped out at $18.5 million in Q3 2025 and bottomed at -$57.4 million in Q1 2025.
• Historically, EBITDA has averaged -$796944.4 across 5 years, with a median of $7.1 million in 2023.
• The sharpest annual moves came in 2023 and 2025: EBITDA jumped 979.36% in 2023, then sank 2416.48% in 2025.
• Over 5 years, EBITDA stood at $964000.0 in 2022, then surged by 979.36% to $10.4 million in 2023, then plunged by 368.24% to -$27.9 million in 2024, then jumped by 166.25% to $18.5 million in 2025, then tumbled by 45.37% to $10.1 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $10.1 million, $8.0 million, and -$22.8 million for Q3 2026, Q2 2026, and Q1 2026 respectively.